Clinical data on EBI-005 for the treatment of dry eye disease and allergic conjunctivitis presented at ARVO 2015

Eleven Biotherapeutics presented clinical data for EBI-005, its novel, protein therapeutic which is in late-stage clinical development for dry eye disease and allergic conjunctivitis, at the Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting.

Clinical data EBI-005 demonstrated a clinically relevant effect in dry eye disease and statistically significant improvements in ocular itching, ocular tearing and nasal symptoms associated with the late phase allergen response in patients with allergic conjunctivitis.

Phase 3 study with EBI-005 in allergic conjunctivitis to be initiated later in 2015

“We are pleased with these data, which further support the important role of interleukin-1 as a key target for ocular surface inflammation, offering a potential new therapy for the treatment of dry eye disease and allergic conjunctivitis,” said Abbie Celniker, PhD, President and Chief Executive Officer of Eleven Biotherapeutics. “We are looking forward to reporting top-line pivotal Phase 3 results for EBI-005 in dry eye disease later this quarter and initiating a Phase 3 study with EBI-005 in allergic conjunctivitis in the second half of this year.”

In an oral presentation entitled, “Comparison of Two Clinical Repeat Allergen Challenge Models to Evaluate EBI-005 in the Late Phase Inflammatory Response in Allergic Conjunctivitis,” Michael H. Goldstein, MD, Chief Medical Officer of Eleven Biotherapeutics, presented data from a Phase 2 study in subjects with moderate to severe allergic conjunctivitis in which EBI-005 was evaluated in two different clinical models adapted for the late phase inflammatory response. Based on these data, EBI-005 will be evaluated utilising a natural environment model in a planned Phase 3 allergic conjunctivitis study of EBI-005 in the second half of this year.

In a poster presentation entitled, “Clinical Development of EBI-005, a Novel Interleukin-1 Receptor Inhibitor, for Patients with Ocular Surface Inflammation,” Eleven Biotherapeutics researchers describe how data related to dosing, disease severity, patient selection, and endpoint selection from previously completed clinical studies shaped the design of pivotal, Phase 3 studies for EBI-005 in dry eye disease. Highlights of the poster include:

• EBI-005 demonstrated an effect in both dry eye disease and allergic conjunctivitis
• EBI-005 reduced the need for rescue artificial tear use in dry eye disease